---
title: "The Nasdaq Biotechnology Index rose by 1.3%, temporarily outperforming the three major U.S. stock indices"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/247012932.md"
description: "The Nasdaq Biotechnology Index rose 1.3%, outperforming the three major U.S. stock indices. Among the constituent stocks, Precigen rose 14.48%, Prime Medicine rose 12.28%, Esperion rose 11.00%, Rocket Pharma rose 10.81%, and Editas Medicine rose 10.44%. In contrast, Grail fell 2.11%, Y mAbs Therapeutics fell 2.22%, Fortrea Holdings fell 2.69%, Silence Therapeutics fell 2.79%, Biomea Fusion fell 2.91%, and Mesoblast fell 9.16%"
datetime: "2025-07-02T14:11:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/247012932.md)
  - [en](https://longbridge.com/en/news/247012932.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/247012932.md)
generator: "portal-rs"
---

# The Nasdaq Biotechnology Index rose by 1.3%, temporarily outperforming the three major U.S. stock indices

Component stocks Precigen rose 14.48%, Prime Medicine rose 12.28%, Esperion rose 11.00%, Rocket Pharma rose 10.81%, Editas Medicine rose 10.44%. Grail fell 2.11%, Y mAbs Therapeutics fell 2.22%, Fortrea Holdings fell 2.69%, Silence Therapeutics fell 2.79%, Biomea Fusion fell 2.91%, Mesoblast fell 9.16%

### Related Stocks

- [PGEN.US](https://longbridge.com/en/quote/PGEN.US.md)
- [PRME.US](https://longbridge.com/en/quote/PRME.US.md)
- [RCKT.US](https://longbridge.com/en/quote/RCKT.US.md)
- [EDIT.US](https://longbridge.com/en/quote/EDIT.US.md)
- [SLN.US](https://longbridge.com/en/quote/SLN.US.md)
- [BMEA.US](https://longbridge.com/en/quote/BMEA.US.md)
- [ESPR.US](https://longbridge.com/en/quote/ESPR.US.md)
- [MESO.US](https://longbridge.com/en/quote/MESO.US.md)

## Related News & Research

- [Prime Medicine Gets FDA Green Light for Gene Editing Study](https://longbridge.com/en/news/300155017.md)
- [Prime Medicine wins FDA IND clearance for PM647 in alpha-1 antitrypsin deficiency](https://longbridge.com/en/news/300070966.md)
- [Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency | PRME Stock News](https://longbridge.com/en/news/300071524.md)
- [Chardan Capital Sticks to Their Buy Rating for Prime Medicine, Inc. (PRME)](https://longbridge.com/en/news/300097621.md)
- [Precigen says FDA grants platform technology designation for AdenoVerse immunotherapy platform](https://longbridge.com/en/news/299630908.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**